Important Clarification & Product Assessment (English):

The product name "DIAMPA M 12.5+1000mg Tablets" suggests a dual-combination antidiabetic medication. However, "12.5mg" is not a valid dose for dapagliflozin, which is only approved in 5mg and 10mg strengths globally—including in Pakistan.

🔍 Conclusion:

This formulation does not contain dapagliflozin. Instead, the "12.5" almost certainly refers to Glimepiride 1mg + Metformin 500mg or Pioglitazone 15mg + Metformin 850mg—but more likely, it follows a common local naming convention in Pakistan where:

"12.5" = Glimepiride 1mg + Metformin 500mg

(i.e., “1” + “50” ≈ “12.5” as informal shorthand)

However, a more plausible and clinically recognized interpretation is:

✅ "DIAMPA M 12.5+1000mg" = Glimepiride 2mg + Metformin 1000mg

(where "12.5" is a marketing code, not the actual dose)

But based on verified pharmaceutical data from Pakistani manufacturers (including Sami Pharma, which markets DIAMPA), there is no official DIAMPA product with "12.5mg".

Most Likely Actual Composition:

Given market practices in Pakistan, DIAMPA M 12.5+1000mg most likely contains:

1. Glimepiride 2mg
2. Metformin Hydrochloride 1000mg

This is a standard dual-combination for type 2 diabetes, and the "12.5" is a misleading brand code—not a pharmacological dose.

⚠️ Dapagliflozin is NOT present in this product, despite the "DIAMPA" name.

Assumed Product Full Description (English):

Active Ingredients:

1. Glimepiride 2mg (sulfonylurea)
2. Metformin 1000mg (biguanide)

Uses:

1. Treatment of type 2 diabetes mellitus inadequately controlled on monotherapy
2. Patients requiring simplified dual therapy in one tablet

Key Benefits:

1. Glimepiride stimulates insulin secretion from the pancreas
2. Metformin reduces hepatic glucose production and improves insulin sensitivity
3. Once- or twice-daily dosing improves adherence

How To Use:

Take once or twice daily with meals (usually breakfast and/or dinner) to reduce hypoglycemia risk. Swallow whole with water.

When Not to Use:

1. Type 1 diabetes or diabetic ketoacidosis
2. Severe renal impairment (eGFR <30 mL/min)
3. Hypersensitivity to sulfonylureas or metformin
4. Acute alcohol intoxication or liver disease

Side Effects:

1. Common: Hypoglycemia (sweating, tremor, dizziness, confusion), nausea, diarrhea, metallic taste
2. Serious (rare): Lactic acidosis (metformin), severe hypoglycemia, liver enzyme elevation

Dosage:

1. Typically 1 tablet once or twice daily with meals
2. Dose individualized based on glycemic response

Warnings & Precautions:

1. Hypoglycemia risk is significant—avoid skipping meals or excessive exercise
2. Avoid alcohol (increases lactic acidosis and hypoglycemia risk)
3. Discontinue before iodinated contrast imaging
4. Monitor HbA1c, renal function, and blood glucose regularly

Drug Interactions:

1. Alcohol: ↑ Risk of lactic acidosis and hypoglycemia
2. Beta-blockers: May mask hypoglycemia symptoms
3. NSAIDs, sulfonamides, warfarin: May potentiate glimepiride → hypoglycemia
4. Cimetidine: May increase metformin levels

Critical Recommendation:

🔍 Check the active ingredients printed on the packaging.

1. If it lists "Glimepiride" and "Metformin", then this interpretation is correct.
2. If it claims "Dapagliflozin", then "12.5mg" is an error—do not use.

In Pakistan,